Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

Axe Cap view

PPH vs PJP: Which Pharma ETF Suits South African Investors?

VanEck's PPH offers a lower-cost, higher-yield alternative to Invesco's PJP, better aligned with long-term income goals in rand terms.

For South African investors looking to gain international pharma exposure, VanEck's PPH stands out as the more attractive option, primarily due to its lower expense ratio (0.36%) and a solid 2% dividend yield. In a world of rising costs, fees matter, especially when holding investments for the long haul. PPH’s portfolio leans heavily on big names like Eli Lilly and Merck, which adds concentration risk but also dependable cash flow—a crucial factor when you consider how rand dividends can supplement income in a volatile currency environment. PJP’s stronger short-term return is tempting, but the higher expense ratio (0.58%) and lower yield (0.9%) make it less compelling for steady rand earners. If the rand suddenly strengthens against the dollar, both ETFs’ attractiveness would be challenged, especially given their US-centric holdings. For South Africans, PPH offers a cleaner, more cost-efficient way to tap into global pharma without excessive fees cutting into returns. this is just our opinion and not financial advice